<a href="https://www.fiercebiotech.com/biotech/infex-following-insmeds-footsteps-advances-lung-disease-candidate-after-clearing-phase-2a" hreflang="en">Infex, following in Insmed’s footsteps, advances lung disease candidate after clearing phase 2a</a>
Infex Therapeutics is advancing its anti-PcrV antibody RESP-X for non-cystic fibrosis bronchiectasis after positive phase 2a trial results, showing fewer exacerbations in patients colonized with Pseudomonas aeruginosa. The company plans to engage with regulators for further development following the trial's success and a recent fundraising effort.
Infex Therapeutics' recent phase 2a trial results for their non-cystic fibrosis bronchiectasis (NCFB) candidate, RESP-X, demonstrated promising efficacy signals despite not reaching conventional statistical significance. This advancement, along with the successful safety profile, positions Infex to engage with regulators for further development. For healthtech investors or professionals, this could signal a potential opportunity for investment or partnership, especially as Infex has recently raised funds to continue advancing its pipeline, which also includes a broad-spectrum metallo-beta-lactamase inhibitor.